146 related articles for article (PubMed ID: 7962650)
1. C-erbB-2 immunostaining: problems with interpretation.
Kay EW; Walsh CJ; Cassidy M; Curran B; Leader M
J Clin Pathol; 1994 Sep; 47(9):816-22. PubMed ID: 7962650
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical staining for the c-erbB-2 gene product in breast aspirates: a preliminary report.
Fernando IN; Allan SM; Sandle J; Dean C; Sacks N; Trott PA
Cytopathology; 1993; 4(4):219-24. PubMed ID: 8104525
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein expression in primary human tumors.
McCann A; Dervan PA; Johnston PA; Gullick WJ; Carney DN
Cancer; 1990 Jan; 65(1):88-92. PubMed ID: 2403483
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different scoring systems for immunohistochemical staining.
Adams EJ; Green JA; Clark AH; Youngson JH
J Clin Pathol; 1999 Jan; 52(1):75-7. PubMed ID: 10343618
[TBL] [Abstract][Full Text] [Related]
5. C-erbB-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2.
Taylor SL; Rudland PS; Barraclough R
Oncol Res; 1999; 11(7):311-7. PubMed ID: 10757445
[TBL] [Abstract][Full Text] [Related]
6. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?
Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
J Clin Pathol; 2004 Jul; 57(7):773-5. PubMed ID: 15220376
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study.
Suwanagool P; Parichatikanond P; Maeda S
Asian Pac J Allergy Immunol; 1993 Dec; 11(2):119-22. PubMed ID: 7915904
[TBL] [Abstract][Full Text] [Related]
8. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
Hameed O; Adams AL; Baker AC; Balmer NE; Bell WC; Burford HN; Chhieng DC; Jhala NC; Klein MJ; Winokur T
Am J Clin Pathol; 2008 Sep; 130(3):425-7. PubMed ID: 18701416
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens.
Taylor SL; Platt-Higgins A; Rudland PS; Winstanley JH; Barraclough R
Int J Cancer; 1998 May; 76(4):459-63. PubMed ID: 9590117
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation.
Chiu KY; Loke SL; Ho FC
J Clin Pathol; 1994 Feb; 47(2):117-21. PubMed ID: 7907612
[TBL] [Abstract][Full Text] [Related]
11. Comparison of radioligand assay and immunostaining for epidermal growth factor receptor in human breast cancer.
Hastrich DJ; Dunn JM; Nicholson S; Newcomb P; Farndon JR
Br J Surg; 1994 Jun; 81(6):853-5. PubMed ID: 8044601
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.
Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S
Anticancer Res; 2019 Apr; 39(4):1953-1957. PubMed ID: 30952738
[TBL] [Abstract][Full Text] [Related]
13. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.
Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D
J Clin Pathol; 1995 Feb; 48(2):129-32. PubMed ID: 7745111
[TBL] [Abstract][Full Text] [Related]
14. Inter-observer variation of p53 immunohistochemistry--an assessment of a practical problem and comparison with other studies.
Kay EW; Barry Walsh CJ; Whelan D; O'Grady A; Leader MB
Br J Biomed Sci; 1996 Jun; 53(2):101-7. PubMed ID: 8757686
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation.
Tannapfel A; Kühn R; Kessler H; Wittekind C
Anal Cell Pathol; 1996 Mar; 10(2):149-60. PubMed ID: 8721956
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.
Lagendijk JH; Mullink H; van Diest PJ; Meijer GA; Meijer CJ
J Clin Pathol; 1999 Apr; 52(4):283-90. PubMed ID: 10474521
[TBL] [Abstract][Full Text] [Related]
17. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas.
Poller DN; Spendlove I; Baker C; Church R; Ellis IO; Plowman GD; Mayer RJ
J Pathol; 1992 Nov; 168(3):275-80. PubMed ID: 1361526
[TBL] [Abstract][Full Text] [Related]
18. A novel image cytometric method for quantitation of immunohistochemical staining of cytoplasmic antigens.
Guillaud M; Matthews JB; Harrison A; MacAulay C; Skov K
Anal Cell Pathol; 1997; 14(2):87-99. PubMed ID: 9313824
[TBL] [Abstract][Full Text] [Related]
19. Investigating Various Thresholds as Immunohistochemistry Cutoffs for Observer Agreement.
Ali A; Bell S; Bilsland A; Slavin J; Lynch V; Elgoweini M; Derakhshan MH; Jamieson NB; Chang D; Brown V; Denley S; Orange C; McKay C; Carter R; Oien KA; Duthie FR
Appl Immunohistochem Mol Morphol; 2017 Oct; 25(9):599-608. PubMed ID: 27093449
[TBL] [Abstract][Full Text] [Related]
20. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
